Adjuvant selection and optimization in the design of an epstein–barr virus–based multi-epitope vaccine against Burkitt lymphoma
- 1Universitas Tanjungpura, Pontianak, Indonesia
- 2Universitas Palangka Raya, Palangka Raya, Indonesia
Abstract
Background: This study aimed to identify and optimize a multi-epitope vaccine construct against Epstein–Barr virus (EBV)-associated Burkitt lymphoma, with particular emphasis on adjuvant selection, using an immunoinformatics approach.
Methods: CTL, HTL, and B-cell epitopes derived from gp350, EBNA1, LMP2A, and BZLF1 were screened based on their predicted immunological properties. We assembled candidate epitopes into multi-epitope vaccine constructs with different configurations and evaluated them using immunoinformatics analyses.
Results: A total of 39 CTL, 21 HTL, and 10 B-cell epitopes met the predefined selection criteria. Five multi-epitope vaccine constructs (R1–R5) were generated and compared. The 50 S ribosomal protein L7/L12 was selected as the adjuvant, and R5 was selected as the final construct based on its comparatively favorable predicted tertiary structure and molecular interactions with TLR2 and TLR4. R5 consisted of 790 amino acids and showed favorable predicted antigenicity (0.6479), solubility, non-allergenicity, and non-toxicity. The predicted population coverage was 98.46% worldwide. Molecular docking demonstrated favorable interactions with TLR2 and TLR4, while iMODS analysis indicated structural stability and favorable dynamic properties.Immune simulation predicted both cellular and humoral immune responses following three administrations at 28-day intervals.
Conclusion: The L7/L12-adjuvanted R5 construct demonstrated favorable predicted immunological, structural, and molecular characteristics in silico. These findings support its consideration as a candidate for further experimental investigation against EBV-associated Burkitt lymphoma. However, experimental validation is required to determine its actual immunogenicity, safety, and protective efficacy.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s43046-026-00423-1.
Related
- Extraction, Structure–Activity Relationships, and Modification of Plant-Derived Polysaccharides: An Integrated Framework for Evidence-Based Method Selection and Bioactivity Optimization—A Review
- QUBO-Based Conformer Selection with Quantum-Classical Hybrid Optimization for Multiconformer Ligand Modeling
- Conservation guided reverse vaccinology for the design of a broadly immunogenic multi-epitope vaccine against monkeypox virus
- Integrated immunoinformatics and molecular dynamics approaches reveal a promising multi-epitope vaccine against hantavirus
- Immunoinformatics design and in vitro evaluation of dendritic cell-targeting brucellosis multi-epitope vaccine based on Omp28 and GroEL
BibTeX
@article{trimurti2026adjuvant,
title = {{Adjuvant selection and optimization in the design of an epstein–barr virus–based multi-epitope vaccine against Burkitt lymphoma}},
author = {Jesika Trimurti and Sari Eka Pratiwi and Syarifah Nurul Yanti Rizki Syahab Asseggaf and Ysrafil Ysrafil},
journal = {Journal of the Egyptian National Cancer Institute},
year = {2026},
month = oct,
doi = {10.1186/s43046-026-00423-1},
url = {https://doi.org/10.1186/s43046-026-00423-1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Adjuvant selection and optimization in the design of an epstein–barr virus–based multi-epitope vaccine against Burkitt lymphoma
AU - Jesika Trimurti
AU - Sari Eka Pratiwi
AU - Syarifah Nurul Yanti Rizki Syahab Asseggaf
AU - Ysrafil Ysrafil
PY - 2026
DA - 2026/10/27
JO - Journal of the Egyptian National Cancer Institute
DO - 10.1186/s43046-026-00423-1
UR - https://doi.org/10.1186/s43046-026-00423-1
AB - Background: This study aimed to identify and optimize a multi-epitope vaccine construct against Epstein–Barr virus (EBV)-associated Burkitt lymphoma, with particular emphasis on adjuvant selection, using an immunoinformatics approach. Methods: CTL, HTL, and B-cell epitopes derived from gp350, EBNA1, LMP2A, and BZLF1 were screened based on their predicted immunological properties. We assembled candidate epitopes into multi-epitope vaccine constructs with different configurations and evaluated them using immunoinformatics analyses. Results: A total of 39 CTL, 21 HTL, and 10 B-cell epitopes met the predefined selection criteria. Five multi-epitope vaccine constructs (R1–R5) were generated and compared. The 50 S ribosomal protein L7/L12 was selected as the adjuvant, and R5 was selected as the final construct based on its comparatively favorable predicted tertiary structure and molecular interactions with TLR2 and TLR4. R5 consisted of 790 amino acids and showed favorable predicted antigenicity (0.6479), solubility, non-allergenicity, and non-toxicity. The predicted population coverage was 98.46% worldwide. Molecular docking demonstrated favorable interactions with TLR2 and TLR4, while iMODS analysis indicated structural stability and favorable dynamic properties.Immune simulation predicted both cellular and humoral immune responses following three administrations at 28-day intervals. Conclusion: The L7/L12-adjuvanted R5 construct demonstrated favorable predicted immunological, structural, and molecular characteristics in silico. These findings support its consideration as a candidate for further experimental investigation against EBV-associated Burkitt lymphoma. However, experimental validation is required to determine its actual immunogenicity, safety, and protective efficacy. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s43046-026-00423-1.
SN - 1110-0362
SN - 2589-0409
ER -